📰 Expanded Access Program News
Page 16 - Expanded Access Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Expanded Access Program. Real-time updates on events, politics, business and more.
May 26, 2022
Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor...
May 25, 2022
Talicias efficacy and safety profile evaluated in patients with H. pylori infection and diabetes mellitus, a large and challenging patient population...
April 27, 2022
/PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced the presentation of new clinical research...
April 27, 2022
/PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced the presentation of new clinical research...
April 18, 2022
- Oral opaganibs reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern...
April 13, 2022
Patients in Vancouver will soon be able to access paid, prescription fentanyl that they can take home and use, an option the doctor leading the program says will allow people to escape "the violent system of trying to see your drug dealer and stay out of withdrawal every day."
April 11, 2022
- Oral opaganibs reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern...
April 7, 2022
Biophytis / Key word(s): Annual ResultsBiophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives 07-Apr-2022 / 08:00 CET/CESTBiophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives  Success of Nasdaq IPO in February 2021 €23.9M o...
March 31, 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 30, 2022--
March 17, 2022
/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its operational...